https://www.selleckchem.com/pr....oducts/envonalkib.ht
Patients who received CFRT were older, smoked more often concurrently with treatment, had higher ECOG performance status, different T and N stage patterns, and more commonly received concurrent chemoradiotherapy and prophylactic cranial irradiation. After propensity score matching for these differences, 72 patients were included, 36 in the HFRT and CFRT cohorts respectively. There was no difference in OS (P=0.724), PFS (P=0.862), any pulmonary (P=0.35, or esophageal (P=0.097) adverse events between cohorts. Skin adverse events were
Curtir
Comentario
Compartilhar
